INSYS Therapeutics Completes Pharmacokinetics (PK) Study of Intranasal Naloxone for Opioid Overdose
October 03, 2017 10:06 ET
|
Insys Therapeutics, Inc.
PHOENIX, Oct. 03, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), announced today that its recently completed pharmacokinetics (PK) study of the company’s...
INSYS Therapeutics Files New Drug Application (NDA) for Buprenorphine Sublingual Spray with FDA
September 29, 2017 09:00 ET
|
Insys Therapeutics, Inc.
PHOENIX, Sept. 29, 2017 (GLOBE NEWSWIRE) -- In advancing its pipeline of innovative medicines, INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), announced today that it filed a New...
INSYS Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference
September 21, 2017 18:00 ET
|
Insys Therapeutics, Inc.
PHOENIX, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the Company”), today announced that Saeed Motahari, President and Chief Executive Officer, and Andrew...
INSYS Therapeutics Hires First Corporate Communications Leader and New Investor Relations Agency
September 21, 2017 16:01 ET
|
Insys Therapeutics, Inc.
PHOENIX, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("INSYS" or "the Company"), today announced the hiring of Joe McGrath as the Company’s Senior Director of Corporate...
Insys Addresses Arizona Attorney General Complaint
September 01, 2017 09:45 ET
|
Insys Therapeutics, Inc.
PHOENIX, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the Company”) today released the following statement: We continue to reiterate our efforts to be part...
Insys Addresses Questions Raised by Illinois Settlement
August 22, 2017 06:50 ET
|
Insys Therapeutics, Inc.
PHOENIX, Aug. 22, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the Company”) today released the following statement: Like so many stakeholders in the healthcare...
Insys Therapeutics Reports Second Quarter 2017 Results
August 03, 2017 06:50 ET
|
Insys Therapeutics, Inc.
PHOENIX, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("INSYS" or "the Company") today announced financial results for the three-month period ended June 30, 2017. ...
Insys Announces Availability of SYNDROS, the First and Only FDA-Approved Liquid Dronabinol, by Prescription
July 31, 2017 06:50 ET
|
Insys Therapeutics, Inc.
PHOENIX, July 31, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the Company”) today announced that SYNDROS™ (dronabinol oral solution), a proprietary, orally...
Insys Therapeutics to Report Second Quarter 2017 Results on August 3, 2017
July 20, 2017 06:50 ET
|
Insys Therapeutics, Inc.
PHOENIX, July 20, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “Company”) today announced that the Company will release its second quarter 2017 financial results on...
Insys Therapeutics, Inc. Appoints Andrew G. Long as Chief Financial Officer
July 18, 2017 06:50 ET
|
Insys Therapeutics, Inc.
PHOENIX, July 18, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) announced today that Andrew G. Long has joined the company as Chief Financial Officer,...